Navigation Links
Cytokinetics announces fundamental research in cardiac myosin activation in the journal Science
Date:3/17/2011

activator of cardiac myosin, was developed to address these limitations.

In this publication, the authors demonstrated that omecamtiv mecarbil binds to the myosin catalytic domain and acts by an allosteric mechanism to increase the transition rate of myosin into the strongly actin-bound force-generating state. Paradoxically, omecamtiv mecarbil inhibits adenosine 5'-triphosphate (ATP) turnover in the absence of actin, which suggests that it stabilizes an actin-bound conformation of myosin. In animal models, omecamtiv mecarbil increases cardiac function by increasing the duration of ejection without changing the rates of cardiac contraction. The authors concluded that cardiac myosin activation may provide a new therapeutic approach for patients with systolic heart failure.

"This ground-breaking publication underscores the quality and robustness of the science at our company which relates to the mechanics and biology of muscle function and that serves as the basis for our portfolio of drug candidates," stated Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "Over several years, our promising research has now resulted in multiple first-in-class compounds that may address unmet clinical needs in a broad array of indications and medical conditions associated with impaired muscle contractility."

Development Status of Omecamtiv Mecarbil

Omecamtiv mecarbil, a novel cardiac muscle myosin activator, has been the subject of a clinical trials program comprised of multiple Phase I and Phase IIa trials conducted under Cytokinetics' sponsorship. This program was designed to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic profiles of both intravenous and oral formulations of omecamtiv mecarbil for the potential treatment of heart failure across the continuum of care, in both hospital and outpatient settings. Two Phase IIa clinical trials of omecamtiv mecarbil from this program have been com
'/>"/>

Contact: Christopher Keenan
ckeenan@cytokinetics.com
415-505-2581
Cytokinetics, Inc.
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Amgen Exercises Option for Exclusive License to Cytokinetics Cardiac Contractility Program That Includes CK-1827452
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Proove Biosciences, ... on the relationship of genetics and hypertension at the International Academy of ... Vancouver, British Columbia, Canada. The event, which boasts an extensive overview of the ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... its investment in the development and manufacture of highly valued cardiac markers used ... scientific team's extensive expertise with protein chemistry has led to the development and ...
(Date:8/26/2015)... , August 26, 2015 Israel Proves ... DiaCardio wins 1 st place  Wayerz comes in ... Israel by venture capital fund JVP, with ... the US, China , Israel ... .  Impressive achievement for the Israeli representatives in ...
(Date:8/26/2015)... ... ... PRC Clinical, a Clinical Trial Management Expert CRO, will be ... California. The Clinical Trial Management Expert CRO seeks to introduce more California-based sponsors to ... , Stem Cell Meeting on the Mesa on October 7-9 in ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... management and reimbursement content ... web-based delivery platform, DALLAS-FORT WORTH, Texas, Jan. 24 ... to help accelerate,advancements in the treatment of cancer, and ... healthcare,information, have joined forces to bring Oncology Metrics, practice,management ...
... Advanced Medical Specialties, a,47-physician oncology practice located in ... entered into an agreement to join US Oncology,s,network. ... oncology,practices in the U.S., "In today,s challenging ... will keep us in the strongest position to ...
... Quintiles,Transnational Corp. today announced the completion of its ... continued,growth under the leadership of founder and current ... team. Gillings and global private,investment firms Bain Capital ... Quintiles, with 3i also becoming a significant investor.,Temasek ...
Cached Biology Technology:Oncology Metrics and E-Expert Reimbursement Partners Announce Joint Marketing and Product Development Agreement 2Oncology Metrics and E-Expert Reimbursement Partners Announce Joint Marketing and Product Development Agreement 3Advanced Medical Specialties Joins US Oncology Network 2Advanced Medical Specialties Joins US Oncology Network 3Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i 2Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i 3
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics Inc. ... human interface solutions, today announced collaboration with Microsoft ... Windows 10. Microsoft leveraged Synaptics, deep expertise in ... system. Through stringent testing, Synaptics, ... certified with Microsoft,s Precision TouchPad (PTP) specification empowering ...
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition ... Component (Hardware, Software, and Service), Sub-Segment (Computer ... Cloud Forensics), Tool Types, Service, Vertical and ... report to their offering. By ...
(Date:7/31/2015)... de julio de 2015 BGI llevará a cabo ... del 22 al 25 de octubre de 2015, en ... conferencia celebra su décimo aniversario este año. Desde su ... de las reuniones anuales más influyentes del mundo en ... las conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... to swallow humans once lived in East Africa, according to ... true crocodile," says Christopher Brochu, associate professor of geoscience. "It ... largest recorded Nile crocodile was less than 21 feet, and ... of a new crocodile species was just published in the ...
... a family of fishes often found in coral reefs and ... to their survival. As part of the International Union ... of scientists has spent the past ten years assessing the ... 20 species (12%) are at risk of extinction if current ...
... his work on developing new treatments for tuberculosis, a ... Challenges Explorations winner, an initiative funded by the Bill ... of MSU,s Department of Microbiology and Molecular Genetics is ... to conditions that mimic human tuberculosis infection. He will ...
Cached Biology News:UI professor identifies largest known crocodile 2One-quarter of grouper species being fished to extinction 2Biosensor illuminates compounds to aid fight against TB 2
... peptidomimetics built on the flexible and ... These microarrays are available as part ... Service. Custom Probe Content ... specified. Thousands of customer specified peptide ...
... OPA1-01009, OPEP-01009 is a 16 amino acid (amino acids 3-18) ... (DFF). The sequence of this peptide is (amino to ... S - V - K - L - R - ... R - K(18). This peptide may be used ...
... standard microarray image analysis software because of ... tools, visualizations, automation capabilities, performance and ease ... every GenePix scanner, and it also imports ... types of arrays. A wide range of ...
... Applications Package Superior Protein Detection and ... ProXPRESS 2D Proteomic Imaging System is a ... and general life science research applications. ProXPRESS ... of all dyes in the UV and ...
Biology Products: